BLR&D Research Career Scientist Award Application

前列腺癌、肾癌和膀胱癌（泌尿系统恶性肿瘤）是最常见的 我们退伍军人的死因。因此，迫切需要 管理这些恶性肿瘤。为了解决这些问题，申请人一直在 自1987年以来，泌尿系统恶性肿瘤领域。申请人的三个主要目标 研究内容：1）探讨肿瘤发生、发展和转移的分子机制 泌尿系统恶性肿瘤。2)鉴定用于诊断和预后的分子生物标志物， 泌尿系统癌症3)使用天然化合物治疗泌尿系统癌症。完成 这些目标，申请人已经收到了几个VA和NIH资助的项目与合作， VA和非VA临床医生和科学家。 申请人在同行评审中发表了350篇科学出版物， 杂志，并有一个杰出的职业生涯为27年的VA系统。在他的职业生涯中， 他在泌尿系统癌症的分子机制研究方面一直处于最前沿。他 研究工作得到了几个NIH/VA资助项目的支持，目前，他有一个VA优点 评审奖和两个NIH资助的RO 1项目。他已经培训了50多名研究员， 他们当中有来自不同研究机构的教职员， 申请人与VA研究者和非VA研究者进行了广泛的合作 资助的项目和科学出版物。申请人是第一个收到 一个REAP（研究增强奖计划）对前列腺癌的部门， 退伍军人事务部（PI：Dahiya，1999-2012年）。他与几位科学家合作， VA临床科学家。 最近，申请人收到了一个关于“遗传生物标志物的作用”的VA程序项目 前列腺癌的临床评估”（PI：Dahiya，Tanaka，Lau，2012年9月10日）， 与四位VA科学家和临床医生合作。在这个项目下，他的团队调查了 SNPs、CpG甲基化、miRNAs和X连锁基因一起是否可以预测 局限性前列腺癌患者具有发生转移的较高风险 更积极的干预。 目前，申请人已获得VA Merit Review奖“Regulation of c-Myc/HIF pathway 肾癌管理”（PI：Dahiya，10/2011-09/2020）和两个NIH RO 1项目 UO 1CA 184966“种族相关前列腺癌的遗传因素”（PI：Dahiya 07/2015-06/2020） 和RO 1CA 199694“使用非编码RNA进行肾癌预后的分子生物标志物 (PI：Dahiya 06/2016-05/2021） 总之，申请人的科学贡献对VA使命至关重要。 他在泌尿系统癌症领域取得了突破性的发现， 对科学界和VA系统的重要资源。申请人的实验室 在表观遗传学领域（DNA甲基化，组蛋白 修饰，染色质重塑），非编码RNA（dsRNA，miRNA），各种 基因及其在诊断、预后、进展、转移和风险评估中的作用， 泌尿系统恶性肿瘤的治疗。这些都是我们退伍军人管理局医疗保健的高优先级项目 系统

Prostate, kidney and bladder cancers (urological malignancies) are the most common cause of death among our Veterans. Therefore, there is an urgent unmet need for the management of these malignancies. To address these issues, the applicant has been working in the field of urological malignancies since 1987. There are three main goals of the applicant's research: 1) To investigate the molecular mechanisms of initiation, progression and metastasis of urological malignancies. 2) To identify molecular biomarkers for diagnosis and prognosis of urological cancers. 3) Treatment of urological cancers using natural compounds. To accomplish these goals, the applicant has received several VA and NIH funded projects in collaboration with VA and Non-VA clinicians and scientists. The applicant has been very productive with 350 scientific publications in peer-reviewed journals and has had a distinguished career for 27 years in the VA system. Throughout his career, he has been at the forefront of research into the molecular mechanisms of urological cancers. His research work is supported by several NIH/VA funded projects and currently, he has one VA Merit Review award and two NIH funded RO1 projects. He has trained more than 50 fellows and most of them are faculty members at various institutions with funded research programs. The applicant has extensively collaborated with VA investigators and non-VA investigators in funded program projects and scientific publications. The applicant was the first one to receive a REAP (Research Enhancement Award Program) on prostate cancer from the Department of Veterans Affairs (PI: Dahiya, 1999-2012). He has trained several scientists in collaboration with VA clinician scientists. Recently, the applicant received a VA program project on the “Role of genetic biomarkers in clinical assessment of prostate cancer” (PIs: Dahiya, Tanaka, Lau, 10-2012-09-2017) in collaboration with four VA scientists and clinicians. Under this program, his team has investigated whether SNPs, CpG methylation, miRNAs and X-linked genes together can predict which localized prostate cancer patients have a higher risk of developing metastasis and thus require more aggressive interventions. Currently, the applicant has a VA Merit Review award “ Regulation of c-Myc/HIF pathway in the management of kidney cancer” (PI: Dahiya, 10/2011-09/2020) and two NIH RO1 projects UO1CA184966 “Genetic factors for race related prostate cancer” (PI: Dahiya 07/2015-06/2020) and RO1CA199694 “Molecular biomarkers for kidney cancer prognosis using non-coding RNAs (PI: Dahiya 06/2016-05/2021) In summary, the applicant's scientific contributions are vitally important to the VA mission. He has made ground breaking discoveries in the field of urological cancers and has also provided significant resources to the scientific community and the VA system. The applicant's laboratory has made several significant contributions to the fields of epigenetics (DNA methylation, histone modification, chromatin remodeling), non-coding RNAs (dsRNA, miRNAs), SNPs of various genes and their roles in diagnosis, prognosis, progression, metastasis and risk assessment and treatment of urological malignancies. These are high priority programs for our VA health care system.